Early measurement of ST2 as a prognostic biomarker for future occurrence of acute GVHD II-IV in a prospective multisite study Save

Date Added
July 17th, 2020
PRO Number
Pro00100472
Researcher
Sophie Paczesny

List of Studies

Keywords
Cancer
Summary

The purpose of this study is to collect two blood specimens and information about participants who are receiving a standard of care bone marrow or stem cell transplant to use and help better understand graft-versus-host disease (GVHD). One potential new way to help researchers better understand GVHD is through a biomarker (a substance found in your blood/tissue) called ST2. The new information learned from this study could then be used in future research for patients undergoing stem cell transplants. This is a non-interventional study (no drugs involved).

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
843-792-9321

Change_preferences

-- OR --

Create_login